Discovery of Novel E3 Ligands for PROTAC Development
Protein degradation induced by PROTACs (PROteolysis TArgeting Chimeras) constitutes a novel modality of drug discovery, with advantages over the traditional approach. This approach is still at infancy and there is a lot to learn in this field. The trainees will work under academic supervisors at University of Toronto, who are experts in chemical tool development in collaboration with Structural Genomics Consortium (SGC), Toronto to expand the number of chemical tools and technologies, which will enhance the scope and understanding of PROTAC drug development. The Structural Genomics Consortium (SGC) is a not-for-profit, public-private-partnership that aims to catalyze drug discovery through open access research. The SGC is expanding its efforts into this novel paradigm of drug discovery. The tools and techniques produced by trainees will greatly contribute to the chemical tool identification for PROTAC project at SGC, Toronto.